Five things for pharma marketers to know: Friday, June 16, 2018

Share this content:

Eli Lilly CEO David Ricks said the drug pricing system needs to change. The CEO said it's time to do away with drug manufacturer rebates, contending only pharmacy benefit managers benefit from their use. (CNBC)


Syneos Health is planning to eliminate dozens of jobs at an Indiana facility. The company said in a letter to state and local officials that 98 positions at a facility in Indianapolis will be affected. It said terminations will begin at the end of July. (IN.gov via STAT)


Kentucky is suing Walgreens as part of its actions to take on the opioid epidemic. The state's attorney general stated that the company, as both a distributor and dispenser, contributed to the crisis by filling large orders frequently. (NPR)


Teva is facing another setback for its CGRP migraine drug. In a late-stage program, the drug was unable to treat patients with chronic cluster headaches. The company plans to continue studying how successfully it treats patients with episodic cluster headaches. (Endpoints)


Bluebird Bio's gene therapy, LentiGlobin, showed significant benefits for patients in clinical trials. Patients with inherited blood disorders who received the latest therapy have not required chronic blood transfusions. The new data will be presented at the European Hematology Association meeting this weekend. (STAT)

Share this content:
Scroll down to see the next article